Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Raphael Dahmen"'
Autor:
David Bode, Lukas Semmler, Paulina Wakula, Niklas Hegemann, Uwe Primessnig, Nicola Beindorff, David Powell, Raphael Dahmen, Hartmut Ruetten, Christian Oeing, Alessio Alogna, Daniel Messroghli, Burkert M. Pieske, Frank R. Heinzel, Felix Hohendanner
Publikováno v:
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-14 (2021)
Abstract Background Sodium–glucose linked transporter type 2 (SGLT-2) inhibition has been shown to reduce cardiovascular mortality in heart failure independently of glycemic control and prevents the onset of atrial arrhythmias, a common co-morbidit
Externí odkaz:
https://doaj.org/article/57d4817c45a544b8a94b775a2cf0aec3
Autor:
Maximilian G. Posch, Niklas Walther, Ele Ferrannini, David R. Powell, Phillip Banks, Suman Wason, Raphael Dahmen
OBJECTIVE Inhibiting sodium–glucose cotransporters (SGLTs) improves glycemic and cardiovascular outcomes in patients with type 2 diabetes (T2D). We investigated the differential impact of selective SGLT2 inhibition and dual inhibition of SGLT1 and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::235ca9e0759259295320417f21733282
https://doi.org/10.2337/figshare.20069063.v1
https://doi.org/10.2337/figshare.20069063.v1
Autor:
Lori Berard, Junlong Wu, Harald Pohlmeier, Irene Nowotny, David C. Klonoff, Raphael Dahmen, Claire Brulle-Wohlhueter
Publikováno v:
Journal of Diabetes Science and Technology. 11:263-269
Background:Insulin glargine 300 U/mL (Gla-300) contains the same active ingredient as glargine 100 U/mL (Gla-100), and provides the same number of units in one-third of the volume. The SoloSTAR®injector pen has been modified to ensure accurate admin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a94d14907acace03b5ddbc7e9b3dfbac
https://doi.org/10.1177/1932296816668877
https://doi.org/10.1177/1932296816668877
Autor:
Robert Jäger, Raphael Dahmen, Roberto Visentin, Anders Boss, Marshall Grant, Chiara Dalla Man, Claudio Cobelli, Thomas Klabunde, Clemens Giegerich
Publikováno v:
Diabetes Technology & Therapeutics
Background: Technosphere® insulin (TI), an inhaled human insulin with a fast onset of action, provides a novel option for the control of prandial glucose. We used the University of Virginia (UVA)/Padova simulator to explore in-silico the potential b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5beda43b6c7f1d4be997209906a7a465
http://hdl.handle.net/11577/3228977
http://hdl.handle.net/11577/3228977
Autor:
Geremia B. Bolli, Raphael Dahmen, Annke D. Hahn, Ronald Schmidt, Reinhard H.A. Becker, Tanja Eisenblaetter, Tim Heise
Publikováno v:
Diabetes Care
OBJECTIVE In vivo, after subcutaneous injection, insulin glargine (21A-Gly-31B-Arg-32B-Arg-human insulin) is enzymatically processed into 21A-Gly-human insulin (metabolite 1 [M1]). 21A-Gly-des-30B-Thr-human insulin (metabolite 2 [M2]) is also found.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db21be74b51ffb1665e9109c27998dfb
http://europepmc.org/articles/PMC3507590
http://europepmc.org/articles/PMC3507590